Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age

Annals of Internal Medicine

Volumn 127, Issue 11, 1997, Pages 955-965

  Salzmann, Peter ^a,b   Kerlikowske, Karla ^a,b   Phillips, Kathryn ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0030686414     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-11-199712010-00001     Document Type: Article

References (43)

1. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2d ed. Baltimore: Williams & Wilkins; 1996.
2. NCAB endorses mammograms for "average risk" women 40-49; screening schedules may vary among individuals. Cancer Lett. 1997;23:4-7.
3. American College of Radiology. Policy Statement: Guidelines for Mammography. Reston, VA: American Coll of Radiology; 1982.
4. The periodic health examination: 2. 1985 update. Canadian Task Force on the Periodic Examination. Can Med Assoc J. 1986;134:724-7.
5. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster V. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273:149-54.
6. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer lnst. 1993;85:1644-56.
7. Brown ML, Fintor L. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res Treat. 1993;25:113-8.
8. Eddy DM. Screening for breast cancer. Ann Intern Med. 1989;111:389-99.
9. Kattlove H, Liberati A, Keeler E, Brook RH. Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package. JAMA. 1995;273:142-8.
10. Eddy DM, Hasselbad V, McGivney W, Hendee W. The value of mammography screening in women under age 50 years. JAMA. 1988;259:1512-9.
11. Sickles EA, Kopans DB. Mammographic screening for women aged 40 to 49 years: the primary care practitioner's dilemma. Ann Intern Med. 1995;122: 534-8.
12. Harris R, Leininger L. Clinical strategies for breast cancer screening: weighing and using the evidence. Ann Intern Med. 1995;122:539-47.
13. Sox HC. Screening mammography in women younger than 50 years of age [Editorial]. Ann Intern Med. 1995;122:550-2.
14. Shapiro S. The call for change in breast cancer screening guidelines [Editorial]. Am J Public Health. 1994;84:10-1.
15. Sickles EA, Kopans DB. Deficiencies in the analysis of breast cancer screening data [Editorial]. J Natl Cancer lnst. 1993;85:1621-4.
16. Elwood JM, Cox B, Richardson AK. The effectiveness of breast cancer screening by mammography in younger women. Online J Curr Clin Trials. 1993;2:Doc No 32.
17. Glasziou PP, Woodward AJ, Mahon CM. Mammographic screening trials for women aged under 50. A quality assessment and meta-analysis. Med J Aust. 1995;162:625-9.
18. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of the Swedish randomised trials. Lancet. 1993;341:973-8.
19. Kerlikowske K. Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. Monogr Natl Cancer lnst. 1997;22:79-86.
20. Lindfors KK, Rosenquist J. The cost-effectiveness of mammographic screening strategies. JAMA. 1995;274:881-4.
21. Feig SA. Mammographic screening of women aged 40-49 years. Benefit, risk, and cost considerations. Cancer. 1995;76:2097-106.
22. Russell LB, Gold MR, Siegel JE, Daniels N. Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172-7.
23. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996:276:1253-8.
24. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-41.
25. Black WC, Tosteson AN. Cost-effectiveness of mammography screening [Letter], JAMA. 1996:275:111.
26. Boer R, van Oortmarssen GJ, de Koning HJ. Cost-effectiveness of mammography screening [Letter]. JAMA. 1996;275:111-2.
27. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-58.
28. DATA 3.0. Cambridge, MA: Treeage Software; 1996.
29. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographie screening for breast cancer. Radiol Clin North Am. 1992;30:187-210.
30. Shapiro S. Periodic Screening for Breast Cancer: The Health Insurance Plan Project and Its Sequelae, 1963-1986. Baltimore. Johns Hopkins Univ Pr; 1988.
31. U.S. Bureau of the Census. Statistical Abstract of the United States. 11th ed. Washington, DC. U.S. Gov Pr Office; 1991:84.
32. Kosary CL, Ries LA, Miller BA, Hankey BF, Harras A, Edwards BK. SEER Cancer Statistics Review, 1973-1992: Tables and Graphs. Bethesda, MD: National Cancer Institute; 1995. NIH publication no. 96-2789.
33. Hall J. Gerard K, Salkeld G, Richardson J. A cost-utility analysis of mammography screening in Australia. Soc Sci Med. 1992;34:993-1004.
34. Brown ML, Fintor L. U.S. Screening mammography services with mobile units: results from the National Survey of Mammography Facilities. Radiology. 1995;195:529-32.
35. Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. AJR Am J Roentgenol. 1995;273:1373-7.
36. Kerlikowske K, Barclay J. Outcomes of modern screening mammography. Monogr Natl Cancer lnst. 1997;22:105-11.
37. Peer PG, Holland R, Hendriks JH, Mravunac M, Verbeek AL. Age-specific effectiveness of the Nijmegen population-based breast cancer-screening program: assessment of early indicators of screening effectiveness. J Natl Cancer lnst. 1994;86:436-41.
38. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer lnst. 1995;87:417-26.
39. de Koning HJ, Boer R. Quantitative interpretation of age-specific mortality reductions form trials by microsimulation. National Institute of Health Consensus Development Conference: Breast Cancer Screening for Women Ages 40-49. Bethesda, MD: 21-23 January 1997.
40. Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA. 1993;270:2444-50.
41. Lee TT, Solomon NA, Heidenreich PA, Oehlert J, Garber AM. Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med. 1997;126:337-46.
42. Harris RP, Fletcher SW, Gonzalez JJ, Lannin DR, Degnan D, Earp JA, et al. Mammography and age: are we targeting the wrong women? A community survey of women and physicians. Cancer. 1991;67:2010-4.
43. Black WC, Nease RF Jr, Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer lnst. 1995;87:720-31.